DATE: April 08, 2021
TIME: 5:00pm CEST
THIS WEBINAR WILL BE AVAILABLE FOR ON-DEMAND VIEWING AT A LATER DATE.
Multi-omics involves the use of different data modalities to study multiple “omes”, such as the genome, transcriptome, epigenome, and/or the proteome, allowing an integrative approach to address complex biological enigmas. In the context of immuno-oncology, this approach enables better characterization of anti-tumor immune responses and identification of biomarkers to help tailor immunotherapeutic strategies. The success and reliability of such analyses rely on the quality of the samples. In this webinar, Miltenyi Biotec will explain how to efficiently prepare cells for genomic analysis that can be applied to other “-omic” analysis, with a special focus on the preparation of cells from tumors.
Prof. Abhishek Garg from KU Leuven has years of experience studying cancer immunology and immunotherapy. Recently he led a multi-partner collaborative investigation on chronically-sensitized states of tumor-infiltrating CD8+ T cells, broadly classifying them as immunotherapy-responsive differentially exhausted, or immunotherapy-resistant severely dysfunctional. Prof. Garg will present in this webinar how they have conducted an orthogonal multi-omics exploration of exhausted/dysfunctional CD8+ T cells across existing and in-house cancer patient cohorts (>4000 patients across different human cancers). This study comprehensively expands clinical knowledge on CD8+ T cell- states, and provides crucial computational/technical resources to guide the design of future T cell-targeting immunotherapy clinical trials.
Learn which steps are important in the preparation of cells prior to genomic analysis, and how to apply these steps to efficiently prepare cells from tumors for high quality and reliable genomic analysis.
Interpret the concept of CD8+ T cell exhaustion/dysfunction as a “continuum of differential states” rather than a definitive state.
Decipher the importance of balanced biomarker approaches for identifying precise clinical CD8+ T cell states, to correctly guide clinical application of immunotherapies and tailor it to appropriate cancer-type/patients.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.